Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Vasil Toskov, Annamaria Cseh, Alexander Claviez, Beatrice Drexler, Natalia Rotari, Stephan Schwarz-Furlan, Matthias Braun, Peter Bader, Peter Lang, Rita Beier, Bernhard Erdlenbruch, Monika Führer, Miriam Erlacher, Charlotte M Niemeyer, Brigitte Strahm, Ayami Yoshimi
We report 5 children with bone marrow failure (BMF) after primary varicella zoster virus (VZV) infection or VZV vaccination, highlighting the highly variable course. Two patients were treated with intravenous immunoglobulins; one had a slow hematologic recovery, and the other was rescued by allogeneic hematopoietic stem cell transplantation (HSCT). Of the 2 patients treated with immunosuppressive therapy with antithymocyte globulin and cyclosporine, one had a complete response, and the other was transplanted for nonresponse...
April 23, 2024: Journal of Pediatric Hematology/oncology
#2
JOURNAL ARTICLE
Yao Li, Guan-Hua Hu, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Pan Suo, Yu Wang, Yi-Fei Cheng, Xiao-Jun Huang
BACKGROUND: Philadelphia chromosome (Ph)-positive B-cell acute lymphoblastic leukemia (ALL) has a high complete remission (CR) rate, but relapse and prolonged measurable residual disease remain serious problems. We sought to describe the CR rate measurable residual disease negative rate and address the results and safety of pediatric patients who underwent after receiving chimeric antigen receptor (CAR) specific for CD19 (CAR-19) followed by hematopoietic stem cell transplantation (HSCT) for the treatment of Ph-positive ALL...
April 23, 2024: Journal of Pediatric Hematology/oncology
#3
REVIEW
Hongtao Li, Yaxin Zheng, Kehai Gao, Chen Tian
To evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched, and 10 eligible studies were included after data extraction and quality evaluation. Meta-analysis showed that compared to single autologous hematopoietic stem cell transplantation, tandem auto-HSCT does not improve OS, EFS or efficacy in MM patients, and may even lead to higher treatment-related mortality (TRM)...
December 2024: Hematology (Amsterdam, Netherlands)
#4
JOURNAL ARTICLE
Bianca Serio, Gabriella Storti, Matteo D'Addona, Lidia Santoro, Camilla Frieri, Danilo De Novellis, Luana Marano, Giovanna De Santis, Roberto Guariglia, Ilenia Manfra, Eleonora Urciuoli, Serena Luponio, Serena Marotta, Denise Morini, Michela Rizzo, Fausto Palmieri, Nicola Cantore, Valentina Giudice, Antonio Maria Risitano, Carmine Selleri
Background: Post-transplant cyclophosphamide (PTCY) is widely used as graft versus host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplant (HSCT) recipients, with reported clinical benefits in patients who underwent transplant from a matched unrelated donor (MUD). However, real-life data on clinical efficacy and safety of PTCY in haploidentical and MUD transplantations are still poor. Methods: In our real-life retrospective observational study, we included a total of 40 consecutive adult patients who underwent haploidentical or MUD HSCT for various hematological malignancies and who received PTCY ( n = 24) or ATG ( n = 16) as GvHD prophylaxis at Hematology Units from hospitals of Salerno and Avellino, Italy, and clinical outcomes were compared...
April 17, 2024: Hematology Reports
#5
JOURNAL ARTICLE
John V Asimakopoulos, Eleni Lalou, George Seferlis, Maria Malliarou, Eliana Konstantinou, Ioannis Drandakis, Ioannis Vasilopoulos, Angeliki N Georgopoulou, Anastasia Kopsaftopoulou, Alexandros Machairas, Alexia Piperidou, Anestis Karapaschalidis, Maria-Ekaterini Lefaki, Dimitrios Galopoulos, Maria-Panagiota Arapaki, Panagiota Petsa, Ekaterini Benekou, Marina P Siakantaris, Athanasios G Papavassiliou, Panagiotis Tsaftaridis, Panayiotis Panayiotidis, Theodoros P Vassilakopoulos, Angeliki Papapanagiotou, Maria K Angelopoulou
Data on antibody response (AR) after vaccination against SARS-CoV2 in hematopoietic stem-cell transplantation setting (HSCT) were initially scarce, mainly due to the exclusion of such patients from approval studies. Shortly after the worldwide application of vaccination against SARS-CoV-2 in vulnerable populations such as patients with hematologic malignancies, limited single-center trials, including HSCT patients, were published. However, there was a great heterogeneity between them regarding the type of underlying malignancy, co-current treatment, type of vaccine, method of AR measurement, and time point of AR measurement...
April 16, 2024: Hematology Reports
#6
JOURNAL ARTICLE
Yahan Li, Fansheng Kong, Guanchen Bai, Yujie Jiang, Wenlu Zhang, Xue Sun, Xiaohui Sui, Ying Li, Mei Ding, Dai Yuan, Xin Wang, Xiaosheng Fang
BACKGROUND: Eltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT). METHODS: Forty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 109 /L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group...
2024: Frontiers in Immunology
#7
JOURNAL ARTICLE
Mitsuhiro Sugimoto, Atsushi Yonezawa, Junya Kanda, Kotaro Itohara, Daiki Hira, Takeo Yamagiwa, Risa Taniguchi, Yuta Hanyu, Mizuki Watanabe, Yasuyuki Arai, Chisaki Mizumoto, Toshio Kitawaki, Tadakazu Kondo, Kouhei Yamashita, Akifumi Takaori-Kondo, Tomohiro Terada
BACKGROUND: Posaconazole is a vital drug to treat and prevent invasive fungal infections. Several factors, such as sex, body weight, total serum proteins, dietary intake, and severe mucositis, affect posaconazole pharmacokinetics (PKs). However, the relevance of other factors that affect the PKs of posaconazole in hematopoietic stem cell transplantation (HSCT) is unknown. This study explored factors influencing the PKs of posaconazole in HSCT recipients and nontransplant patients with hematological diseases...
April 4, 2024: Therapeutic Drug Monitoring
#8
JOURNAL ARTICLE
Saranthorn Apasuthirat, Nopporn Apiwattanakul, Usanarat Anurathapan, Nintita Sripaiboonkij Thokanit, Karan Paisooksantivatana, Ekawat Pasomsub, Suradej Hongeng, Samart Pakakasama
INTRODUCTION: Immune reconstitution (IR) kinetics of paediatric patients underwent haploidentical haematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PTCy) have not been extensively studied. We compared IR patterns of children receiving HSCT from haploidentical (n = 92) and HLA-matched donors (n = 36), and analysed risk factors for viral infection in these patients. METHODS: We prospectively measured lymphocyte subset numbers before HSCT and at 1, 3, 6 and 12 months after HSCT...
April 22, 2024: International Journal of Laboratory Hematology
#9
REVIEW
Chi-Cheng Li, Xavier Cheng-Hong Tsai, Wei-Han Huang, Tso-Fu Wang
Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival...
2024: Tzu chi medical journal
#10
REVIEW
Tahereh Rostami, Mohammad Reza Rostami, Amir Hossein Mirhosseini, Saeed Mohammadi, Mohsen Nikbakht, Hediyeh Alemi, Naghmeh Khavandgar, Soroush Rad, Ghasem Janbabai, Seied Asadollah Mousavi, Azadeh Kiumarsi, Amir Kasaeian
BACKGROUND: Graft failure (GF) is a rare but serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of graft failure remains the most advisable approach as there is no clear recommendation for the best strategies for reversing this complication. Administration of growth factor, additional hematopoietic progenitor boost, or a salvage HSCT are current modalities recommended for the treatment of GF. Autologous recovery without evidence of disease relapse occurs rarely in patients with GF, and in the absence of autologous recovery, further salvage transplantation following a second conditioning regimen is a potential treatment option that offers the best chances of long-term disease-free survival...
April 22, 2024: Stem Cell Research & Therapy
#11
REVIEW
Lisa M Christian, Janice K Kiecolt-Glaser, Steve W Cole, Christin E Burd, Annelise A Madison, Stephanie J Wilson, Ashley E Rosko
Multiple myeloma (MM) is an incurable cancer and is the leading indication for autologous hematopoietic stem cell transplantation (HSCT). To be eligible for HSCT, a patient must have a caregiver, as caregivers play a central role in HSCT preparation and recovery. MM patients remain on treatment indefinitely, and thus patients and their caregivers face long-term challenges including the intensity of HSCT and perpetual therapy after transplant. Importantly, both patients and their caregivers show heightened depressive and anxiety symptoms, with dyadic correspondence evidenced and caregivers' distress often exceeding that of patients...
April 19, 2024: Brain, Behavior, and Immunity
#12
REVIEW
Soumalya Chakraborty, Aditya Kumar Gupta, Neerja Gupta, Jagdish Prasad Meena, Rachna Seth, Madhulika Kabra
Storage disorders are a group of inborn errors of metabolism caused by the defective activity of lysosomal enzymes or transporters. All of these disorders have multisystem involvement with variable degrees of neurological features. Neurological manifestations are one of the most difficult aspects of treatment concerning these diseases. The available treatment modalities for some of these disorders include enzyme replacement therapy, substrate reduction therapy, hematopoietic stem cell transplantation (HSCT) and the upcoming gene therapies...
April 19, 2024: Indian Journal of Pediatrics
#13
JOURNAL ARTICLE
Priya H Marathe, Valeria Santibanez, Paul A Meyers, Maria L Padilla, Danielle N Friedman
Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial pneumonia with distinct clinicopathologic features. It has been associated with exposure to hematopoietic stem cell transplantation (HSCT) and classical alkylating agents. Here, we highlight PPFE as a late complication of childhood cancer therapy by describing the cases of four survivors of childhood cancer with a diagnosis of treatment-related PPFE. All patients received high-dose alkylating agents. PPFE should be considered in the differential diagnosis of restrictive lung disease in patients with history of exposure to alkylating agents or HSCT...
April 18, 2024: Pediatric Blood & Cancer
#14
MULTICENTER STUDY
Michael D Keller, Patrick J Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C Dvorak, Michael R Verneris, Donald B Kohn, Sung-Yun Pai, Blachy J Dávila Saldaña, Benjamin Hanisch, Troy C Quigg, Roberta H Adams, Ann Dahlberg, Shanmuganathan Chandrakasan, Hasibul Hasan, Jemily Malvar, Mariah A Jensen-Wachspress, Christopher A Lazarski, Gelina Sani, John M Idso, Haili Lang, Pamela Chansky, Chase D McCann, Jay Tanna, Allistair A Abraham, Jennifer L Webb, Abeer Shibli, Amy K Keating, Prakash Satwani, Pawel Muranski, Erin Hall, Michael J Eckrich, Evan Shereck, Holly Miller, Ewelina Mamcarz, Rajni Agarwal, Satiro N De Oliveira, Mark T Vander Lugt, Christen L Ebens, Victor M Aquino, Jeffrey J Bednarski, Julia Chu, Suhag Parikh, Jennifer Whangbo, Michail Lionakis, Elias T Zambidis, Elizabeth Gourdine, Catherine M Bollard, Michael A Pulsipher
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed a phase II multicenter study (NCT03475212) for the treatment of pediatric patients with inborn errors of immunity and/or post allogeneic hematopoietic stem cell transplant with refractory viral infections using partially-HLA matched VSTs targeting cytomegalovirus, Epstein-Barr virus, or adenovirus...
April 18, 2024: Nature Communications
#15
JOURNAL ARTICLE
Anastasia V Pavlova, Ivan V Zvyagin, Mikhail Shugay
An individual's T-cell repertoire constantly changes under the influence of external and internal factors. Cells that do not receive a stimulatory signal die, while those that encounter and recognize a pathogen or receive a co-stimulatory signal divide, resulting in clonal expansions. T-cell clones can be traced by monitoring the presence of their unique T-cell receptor (TCR) sequence, which is assembled de novo through a process known as V(D)J rearrangement. Tracking T cells can provide valuable insights into the survival of cells after hematopoietic stem cell transplantation (HSCT) or cancer treatment response and can indicate the induction of protective immunity by vaccination...
2024: Frontiers in Immunology
#16
JOURNAL ARTICLE
Karam Ashouri, Krithika Chennapan, Anastasia Martynova, Samvel Nazaretyan, Amir Ali, Anush Aram Ginosyan, Eric Tam, Abdullah Ladha, Karrune Woan, Preet Chaudhary, Imran Siddiqi, George Yaghmour
No abstract text is available yet for this article.
April 2024: EJHaem
#17
JOURNAL ARTICLE
Osamu Imataki, Shunsuke Yoshida, Tomoya Ishida, Haruyuki Fujita, Makiko Uemura
A literature review does not provide information about the safety of autologous hematopoietic stem cell transplantation (HSCT) in a recipient who has previously received allogeneic HSCT. We treated a 69-year-old woman with diffuse large B cell lymphoma. The patient received autologous stem cell transplantation (ASCT) in the second complete remission of malignant lymphoma. The patient had undergone allogeneic hematopoietic SCT (allo-HSCT) for chronic myeloid leukemia 20 years ago. Chronic myeloid leukemia had been in complete remission for the previous 20 years...
April 2024: EJHaem
#18
JOURNAL ARTICLE
Qianqian Wang, Hong Xu, Wei Yu, Lingjie Sun, Hongguo Zhao, Xue Shi
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for severe aplastic anemia (SAA). It is known that SAA can evolve into malignant clonal diseases, such as acute myeloblastic leukemia (AML) or myelodysplastic syndrome. However, the transformation of SAA into AML after allo-HSCT is a rare phenomenon. Here, we report a case of SAA transformed into AML after patient received human leucocyte antigen (HLA)-matched sibling peripheral blood stem cell transplantation...
April 18, 2024: American Journal of Case Reports
#19
REVIEW
Tariq Kewan, Maximillian Stahl, Jan Philipp Bewersdorf, Amer M Zeidan
PURPOSE OF REVIEW: Myelodysplastic syndromes/neoplasms (MDS) represent a diverse group of pathologically distinct diseases with varying prognoses and risks of leukemia progression. This review aims to discuss current treatment options for elderly patients with MDS, focusing on patients ineligible for intensive chemotherapy or allogenic hematopoietic stem cell transplantation (HSCT). The challenges associated with treatment in this population and emerging therapeutic prospects are also explored...
April 18, 2024: Current Hematologic Malignancy Reports
#20
JOURNAL ARTICLE
Gabriel Salinas Cisneros, Christopher C Dvorak, Janel Long-Boyle, Sandhya Kharbanda, Kristin A Shimano, Alexis Melton, Julia Chu, Lena E Winestone, Jasmeen Dara, James N Huang, Michelle L Hermiston, Matt Zinter, Christine S Higham
INTRODUCTION: Sinusoidal obstructive syndrome (SOS), or veno-occlusive disease (VOD), of the liver has been recognized as a complex, life-threatening complication in the post-hematopoietic stem cell transplant (HSCT) setting. The diagnostic criteria for SOS have evolved over the last several decades with a greater understanding of the underlying pathophysiology, with two recent diagnostic criteria introduced in 2018 (EBMT criteria) and 2020 (Cairo criteria). OBJECTIVE: We sought out to evaluate the performance characteristics in diagnosing and grading SOS in pediatric patients of the four different diagnostic criteria (Baltimore, Modified Seattle, EBMT, and Cairo) and severity grading systems (defined by the EBMT and Cairo criteria)...
April 15, 2024: Transplantation and cellular therapy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
